Fatigue · participants with quiescent IBD
4 findings from 1 review
no estimate extracted
1 study · 27 participants
Very low
no estimate extracted
1 study · 27 participants
Very low
no estimate extracted
1 study · 27 participants
Very low
Show 1 more finding
Adverse events: · participants with quiescent IBD
1 finding from 1 review
Serious adverse events ‐ not reported · participants with quiescent IBD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events ‐ not reported · participants with quiescent IBD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatigue · participants with quiescent IBD
4 findings from 1 review
no estimate extracted
1 study · 29 participants
Very low
no estimate extracted
1 study · 29 participants
Very low
no estimate extracted
1 study · 29 participants
Very low
Show 1 more finding
Adverse events: · participants with quiescent IBD
1 finding from 1 review
Serious adverse events ‐ not reported · participants with quiescent IBD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events ‐ not reported · participants with quiescent IBD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Placebo Comparator · surgically induced remission in Crohn's disease
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
Placebo (16 RCTs; 935 participants) · surgically induced remission in Crohn's disease
1 finding from 1 review
Intervention not reported
Placebo (8 RCTs; 507 participants) · surgically induced remission in Crohn's disease
1 finding from 1 review
Intervention not reported
Placebo (10 RCTs; 531 participants) · surgically induced remission in Crohn's disease
1 finding from 1 review
Intervention not reported
PPI versus placebo Symptomatic outcome measures · patients with heartburn remission in gastro‐oesophageal reflux disease‐like symptoms
The intervention leads to lower PPI versus placebo Symptomatic outcome measures (high certainty).
1 finding from 1 review
Intervention not reported
H2RA versus placebo · patients with heartburn remission in gastro‐oesophageal reflux disease‐like symptoms
The intervention probably leads to lower H2RA versus placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Prokinetic versus placebo · patients with heartburn remission in gastro‐oesophageal reflux disease‐like symptoms
1 finding from 1 review
Intervention not reported
PPI versus placebo · patients with heartburn remission in endoscopy negative reflux disease
The intervention probably leads to lower PPI versus placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
H2RA versus placebo · patients with heartburn remission in endoscopy negative reflux disease
The intervention probably leads to lower H2RA versus placebo (moderate certainty).
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
Infliximab probably leads to lower clinical relapse (at 30‐32 weeks, CDAI > 150) compared with placebo (moderate certainty).
1 finding from 1 review
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes loss of clinical response (at 32 weeks, less than 70 points in CDAI… compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 32‐54 weeks) compared with placebo (very low certainty).
1 finding from 1 review